Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset

European Journal of Immunology - Tập 50 Số 12 - Trang 2025-2040 - 2020
Patrícia Figueiredo‐Campos1,2, Birte Blankenhaus1,2, Catarina Mota3,2, Andréia Gomes2, Marta Serrano2, Silvia Ariotti2, Catarina Costa2, Helena Nunes‐Cabaço2, António M. Mendes2, Pedro Gaspar3, Maria Conceição Pereira Santos2, Fernanda Rodrigues2, Jorge Condeço4, Maria Antónia Escoval4, Matilde Santos4, Mário Ramirez2, José Melo‐Cristino2, J. Pedro Simas5,2, Eugenia Vasconcelos4, Ângela Afonso2, Neil Hunter2
1Co-first authors
2Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
3Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
4Instituto Português do Sangue e Transplantação (IPST) Lisbon Portugal
5Instituto de Ciências de Saúde Universidade Católica Portuguesa Lisboa Portugal

Tóm tắt

AbstractSARS‐CoV‐2 has emerged as a human pathogen, causing clinical signs, from fever to pneumonia—COVID‐19—but may remain mild or asymptomatic. To understand the continuing spread of the virus, to detect those who are and were infected, and to follow the immune response longitudinally, reliable and robust assays for SARS‐CoV‐2 detection and immunological monitoring are needed. We quantified IgM, IgG, and IgA antibodies recognizing the SARS‐CoV‐2 receptor‐binding domain (RBD) or the Spike (S) protein over a period of 6 months following COVID‐19 onset. We report the detailed setup to monitor the humoral immune response from over 300 COVID‐19 hospital patients and healthcare workers, 2500 University staff, and 198 post‐COVID‐19 volunteers. Anti‐SARS‐CoV‐2 antibody responses follow a classic pattern with a rapid increase within the first three weeks after symptoms. Although titres reduce subsequently, the ability to detect anti‐SARS‐CoV‐2 IgG antibodies remained robust with confirmed neutralization activity for up to 6 months in a large proportion of previously virus‐positive screened subjects. Our work provides detailed information for the assays used, facilitating further and longitudinal analysis of protective immunity to SARS‐CoV‐2. Importantly, it highlights a continued level of circulating neutralising antibodies in most people with confirmed SARS‐CoV‐2.

Từ khóa


Tài liệu tham khảo

10.1073/pnas.0403492101

10.1371/journal.pmed.0030525

Suthar M. S., 2020, Rapid generation of neutralizing antibody responses in COVID‐19 patients, medRxiv

10.1038/s41586-020-2456-9

10.1128/JVI.77.16.8801-8811.2003

10.1016/j.cell.2020.02.052

10.1016/j.cell.2020.03.045

10.1016/j.cell.2020.02.058

10.1038/s41591-020-0913-5

10.3201/eid2607.200841

10.1038/s41467-020-17317-y

10.1002/cpmc.100

10.1016/j.cmi.2018.10.016

10.1002/iid3.192

10.1111/j.1469-0691.2004.01009.x

Wajnberg A., 2020, SARS‐CoV‐2 infection induces robust, neutralizing antibody responses that are sTable for at least three months, medRxiv

10.1001/jama.2020.3786

10.1016/S2352-3018(20)30111-9

10.1111/hiv.12911

Group R. C., 2020, Dexamethasone in Hospitalized Patients with Covid‐19 ‐ Preliminary Report, N. Engl. J. Med.

10.1038/nri.2016.90

10.3389/fpubh.2020.00152

10.1016/S0140-6736(20)30526-2

10.4049/jimmunol.1303400

10.1189/jlb.0811427

10.1056/NEJMoa2006100

Behrens G. M., 2020, Strategic anti‐SARS‐CoV‐2 serology testing in a low prevalence pandemic: The COVID‐19 Contact (CoCo) Study in health care professionals, medRxiv

10.1016/S0140-6736(20)31483-5

10.1016/S0140-6736(20)31304-0

10.1038/s41591-020-0897-1

Addetia A., 2020, Neutralizing antibodies correlate with protection from SARS‐CoV‐2 in humans during a fishery vessel outbreak with high attack rate, medRxiv

10.1016/j.cell.2020.05.015

Braun J., 2020, Presence of SARS‐CoV‐2 reactive T cells in COVID‐19 patients and healthy donors, medRxiv

Gangaev A., 2020, Profound CD8 T cell responses towards the SARS‐CoV‐2 ORF1ab in COVID‐19 patients, Researchsquare

10.1038/s41586-020-2550-z

Oguntuyo K. Y., 2020, Quantifying absolute neutralization titers against SARS‐CoV‐2 by a standardized virus neutralization assay allows for cross‐cohort comparisons of COVID‐19 sera, medRxiv

Thông tin
Thông tin xuất bản

European Journal of Immunology

Tập 50 Số 12

2025-2040

Thông tin tác giả